An Observational Study Evaluating Patient Satisfaction and Quality of Life Associated With Switching Insulin

Resource Utilisation and Patient Satisfaction With SWitching INsulin (SWING)

The purpose of this study is to estimate the direct costs associated with switching, in either direction, between a rapid-acting analog therapy and short-acting human insulin therapy within the first year following the switch. The additional goals are: 1)to assess the impact of a switch from or to a rapid-acting analog insulin therapy on patient treatment satisfaction, 2) to assess the impact of a switch from or to a rapid-acting analog insulin therapy on patient quality of life, 3) to assess the impact of switch from or to the rapid-acting analog insulin therapy on the quality of metabolic control and, 4) to estimate the total costs (direct and indirect) associated with switching, in either direction between rapid-acting analog and short-acting human insulin within the first year following the switch.

Inclusion Criteria:

• are at least 18 years of age
• according to the clinical judgement of the investigator have been diagnosed with type II diabetes
• have presented within the normal course of care
• at the baseline visit are being treated with any therapy including a rapid-acting analog insulin component or any therapy including a short-acting human insulin component and are switching from one form of therapy to the other
• are not simultaneously participating in a study that includes an investigational drug or procedure at entry into the study
• have been fully informed and have given their written consent for the use of their data
• have a sufficient understanding of the primary language of the country such that they will be able to complete the questionnaires

Exclusion Criteria:

• no specific exclusion criteria exist for this study